1 option
Clinical review report : indication: For the symptomatic treatment of lower-limb spasticity in pediatric patients 2 years of age and older. AbobotulinumtoxinA (Dysport therapeutic) (Ipsen biopharmaceuticals Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Outcome assessment (Medical care).
- Physical Description:
- 1 online resource (130 pages)
- Edition:
- Final with redacations.
- Place of Publication:
- Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018.
- Summary:
- The objective of this report is to perform a systematic review of the beneficial and harmful effects of abobotulinumtoxinA (aboBoNTA) for the symptomatic treatment of lower-limb spasticity in pediatric patients two years of age and older.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.